HeartStent gets funds for revolutionary coronary device
This article was originally published in Clinica
Executive Summary
HeartStent, a development-stage medical device company with a device which it hopes could redefine the coronary artery disease market and cut many hundreds of million dollars from annual healthcare costs worldwide, has raised $12.8 million in private financing in order to continue development of the revolutionary device.